ArticleMolecules (Basel, Switzerland)2021
Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Treatment of Reactive Histiocytosis With Oclacitinib: A Retrospective Case Series of 10 Dogs.Veterinary dermatology · 2026Article
- Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis.Veterinary sciences · 2026Review
- Periostin: a potential biomarker for diagnosis and treatment monitoring in canine atopic dermatitis.The veterinary quarterly · 2025Article
- Drug Repurposing in Veterinary Oncology: Myth or Reality?Veterinary sciences · 2025Review
- Evaluation of filaggrin 2 expression in dogs with atopic dermatitis before and after oclacitinib maleate administration.Veterinary dermatology · 2025Article
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat.Veterinary sciences · 2025Article
- Case Report: The potential association with polyglandular autoimmune syndrome in a dog following long-term oclacitinib therapy.Frontiers in veterinary science · 2025Article
- Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.BMC veterinary research · 2024Article
- Immunological characteristics of CD103Parasitology research · 2023Article
- CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential.Experimental & molecular medicine · 2023Review
- Effect of IL-27, Teriflunomide and Retinoic Acid and Their Combinations on CD4Molecules (Basel, Switzerland) · 2022Article
- Severe Toxicosis Secondary to Accidental Oclacitinib Ingestion in Three Cats.Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of the present study was to broaden the knowledge and understanding of the effects of oclacitinib (OCL), a Janus kinase inhibitor, on T cells in the context of both the immune mechanisms underlying anti-inflammatory and anti-allergic properties of the drug and its safety. The results indicate that beneficial effects of OCL in the treatment of skin allergic diseases may be partially mediated by the inhibition of IL-4 production in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.